Scientists unveil new obesity drug that reprograms fat and energy use
Sanatate
European Association for the Study of Diabetes Sep 18 2025 Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September). The treatment of obesity has been transformed in recent years by glucagon -like peptide-1 (GLP-1) receptor agonists such as semaglutide , which reduce appetite, slow the release of food from the stomach and increase feelings
din zilele anterioare